OWL Metabolomics Announces Scientific and Commercial Participation at The Liver Meeting® 2023

(Bilbao, Spain, October 11, 2023) OWL Metabolomics will repeat its involvement at the upcoming The Liver Meeting® 2023 hosted by the American Association for the Study of Liver Diseases on November 10-14, 2023 in Boston, MA.

This year, OWL will be involved as a Scientific Contributor presenting recent metabolomics-based liver research findings in poster sessions, as described below:

•2015-A. AT-RISK MASH IDENTIFICATION USING AN ALGORITHM THAT COMBINES
FIB-4 + MASEF (METABOLOMICS-ADVANCED STEATOHEPATITIS FIBROSIS SCORE)
Saturday, November 11; 1:00 PM – 2:00 PM. Hall A (plaza level)

•2048-A. GENETIC ALGORITHMS REVEAL POTENTIAL TO STRATIFY NAFLD HETEROGENEITY
Saturday, November 11; 1:00 PM – 2:00 PM. Hall A (plaza level)

OWL’s commercial participation will include a collaboration in the industry booth of CIMA Sciences in the Hall A of the Hynes Convention Center (Booth #B1222), together with LUXOR Scientific. OWL staff welcome your visit to our booth and suggest that a time be reserved for a brief discussion during the standard booth hours: Saturday 11 (6:00-7:30 p.m.), Sunday 12 (9:30 a.m.-4:30 a.m.) and Monday 13 (9:30 a.m.-4:30 a.m.).

Please contact the OWL Meeting Administrator, Miguel Campo, (mcampo@owlmetabolomics.com), to help identify a meeting time with our staff.

OWL’s long-standing focus on fatty liver disease progression, diagnosis

OWL Metabolomics collaborates with numerous pharma and biotech research organizations in the liver field throughout the world by constructing unique metabolomics-based analyses to determine specific changes in disease status and changes in disease severity within a variety of fatty liver patient types.
OWL has been involved in active MASH (Metabolic dysfunction-Associated SteatoHepatitis)-related metabolomic research for over 17 years, including metabolomics-based pre-clinical analysis in early-candidate drug studies, verification of treatment-arm parity at baseline, active human trial monitoring (i.e., surrogate marker of drug effect, monitoring of therapeutic impact / dose effects), and the development of tailored companion diagnostics to more accurately predict potential patient responders to a given drug treatment.
In addition to the detailed MASH research collaborations with pharma, OWL Metabolomics has produced and validated the OWLiver® panel, the only NON-invasive laboratory test based on metabolomics technology that determines liver activity through the evaluation of 28 metabolites, with a primary goal of reducing the need for more invasive or more expensive testing modalities, including the invasive liver biopsy. Today’s international ‘gold-standard’ for the definitive diagnosis of MASH remains a cumbersome and expensive invasive tissue biopsy procedure. The key benefit of such blood-based advanced testing is that it can be performed safely at frequent intervals allowing patient monitoring.

History of OWL Metabolomics

OWL Metabolomics, a Rubió Group company, is a global metabolomics service provider to the pharma industry with a main focus supporting clinical trials in liver diseases and other prevalent human diseases as well as research in indications where metabolomic plays a key role, including drug therapy monitoring and biomarker discovery.
OWL Metabolomics is also committed to the identification, validation and global commercialization of novel diagnostic assays for liver diseases. Since its inception in 2002, OWL Metabolomics has pioneered unique diagnostic research within the fatty liver space, a field of considerable focus in MASH drug development.